Article

Model Predicts Risk of Invasive Breast Cancer

Treating modifiable risk factors could enhance breast cancer prevention.

A model that predicts the absolute risk of invasive breast cancer was recently developed in an effort to improve prevention.

A study published in JAMA Oncology used previously collected data to help develop a more empirical model. The model contained 92 susceptibility single nucleotide polymorphisms (SNPs), as well as other epidemiologic factors including anthropometric, family history, lifestyle, and menstrual/reproductive factors.

The model revealed that when all risk factors were included, the range of average absolute risk was 4.4% to 23.5% for women at the bottom and top of risk, respectively.

Women who were at the highest level of risk because of non-modifiable risk factors, low body mass index (BMI), not smoking or drinking, and not using menopausal hormone therapy, were found to have risks similar to an average woman in the general population. Researchers believe that as many as 28.9% of all breast cancers could be prevented if every Caucasian woman in the United States was at the lowest risk for the modifiable risk factors.

“Our results illustrate the potential value of risk stratification to improve breast cancer prevention, particularly to aid decisions on risk factor modification at the individual level,” the study authors wrote. “The effect of such models for improving the cost-benefit ratio of population-based prevention programs will depend on the implementation cost of risk assessment.”

Limitations to the study included the inability to evaluate several known risk factors for breast cancer that had data that was unavailable.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards